Tag: ampligen
October 10, 2018
Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center
Hemispherx Biopharma (NYSE:HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in... September 18, 2018
Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe
Hemispherx Biopharma (NYSE:HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen (rintatolimod),... January 11, 2017
Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that the rintatolimod European early access program (EAP) designed to... November 10, 2016
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update
Hemispherx Biopharma announced today that it anticipates filing its 2016 third quarter financial results for the quarter ended September 30,... October 19, 2016
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone
Hemispherx Biopharma announced today that it has completed its technology transfer of the Ampligen® manufacturing processes to Avrio Biopharmaceuticals. August 31, 2016
Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering
PHILADELPHIA, Aug. 31, 2016 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”), announced today that it has... August 23, 2016
